Cytokinetics Inc (NASDAQ:CYTK) price on Wednesday, May 21, fall -4.13% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $31.31.
A look at the stock’s price movement, the close in the last trading session was $32.66, moving within a range at $30.98 and $32.745. The beta value (5-Year monthly) was 0.81. Turning to its 52-week performance, $61.38 and $29.31 were the 52-week high and 52-week low respectively. Overall, CYTK moved -17.19% over the past month.
Cytokinetics Inc’s market cap currently stands at around $3.74 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-05.
The average forecast suggests up to a 706.05% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 23.59M, representing a 27.68% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CYTK is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
12 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 11 recommend CYTK as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CYTK’s current price about -10.87% and -18.77% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 37.22, while 7-day volatility ratio is 5.23% and 5.42% in the 30-day chart. Further, Cytokinetics Inc (CYTK) has a beta value of 0.60, and an average true range (ATR) of 2.14. Analysts have given the company’s stock an average 52-week price target of $61, forecast between a low of $55 and high of $67. Looking at the price targets, the low is -75.66% off current price level while to achieve the yearly target high, price needs to move -113.99%. Nonetheless, investors will most likely welcome a -94.83% jump to $61 which is the analysts’ median price.
If we refocus on Cytokinetics Inc (NASDAQ:CYTK), historical trading data shows that trading volumes averaged 2.19 over the past 10 days and 2.14 million over the past 3 months. The company’s latest data on shares outstanding shows there are 119.22 million shares.
The 2.27% of Cytokinetics Inc’s shares are in the hands of company insiders while institutional holders own 116.07% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 14.48 million on 2025-04-30, giving us a short ratio of 6.43. The data shows that as of 2025-04-30 short interest in Cytokinetics Inc (CYTK) stood at 1585.0 of shares outstanding, with shares short rising to 14.33 million registered in 2025-03-31. Current price change has pushed the stock -33.44% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CYTK stock continues to rise going into the next quarter.
